Related Experiment Videos
NF-kappaB: a therapeutic target in inflammatory diseases
C L Curran1, T S Blackwell, J W Christman
1Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, and The Department of Veterans Affairs, Nashville, TN, USA.
Expert Opinion on Therapeutic Targets
|July 5, 2005
Summary
The transcription factor Nuclear Factor kappa B (NF-kappaB) plays a role in inflammatory diseases. While many agents can inhibit NF-kappaB in studies, clinical applications remain challenging, necessitating further research for targeted therapies.
Area of Science:
- Molecular Biology
- Immunology
- Biochemistry
Background:
- The transcription factor Nuclear Factor kappa B (NF-kappaB) is a key mediator in inflammatory disease pathogenesis.
- NF-kappaB signaling is implicated in both acute and chronic inflammatory conditions.
Purpose of the Study:
- To review agents and strategies that can abrogate NF-kappaB activity.
- To discuss the clinical feasibility of NF-kappaB inhibiting therapies.
Main Methods:
- Review of scientific literature on NF-kappaB inhibitors.
- Analysis of in vitro and in vivo studies demonstrating NF-kappaB inhibition.
- Evaluation of clinical trial data and therapeutic challenges.
Main Results:
- Numerous agents, including antioxidants, corticosteroids, and proteasome inhibitors, show potential to inhibit NF-kappaB.
- Despite promising preclinical data, clinical translation of NF-kappaB blocking therapies has faced significant hurdles.
- The complex signaling pathways of NF-kappaB activation are increasingly understood.
Conclusions:
- Targeting NF-kappaB remains a significant goal for treating inflammatory diseases.
- Further elucidation of NF-kappaB signaling pathways may lead to the identification of more specific and effective inhibitors.
- Development of clinically feasible NF-kappaB inhibitors is an ongoing area of research.